Journal of Clinical & Experimental Dermatology Research
Open Access
ISSN: 2155-9554
ISSN: 2155-9554
Fariz Yahya , Sargunan Sockalingam, Suryaprakash Mishra, G S Ramakrishna, Chan-droday Biswas and Steffen Jugl
Department of Medicine, University Malaya Medical Centre, Kuala Lumpur
Novartis Corporation (Malaysia) Sdn. Bhd, Malaysia
Novartis Healthcare Pvt. Ltd., Hyderabad, India
Novartis Pharma AG, Basel, Switzerland
Posters & Accepted Abstracts: J Clin Exp Dermatol Res
Statement of the Problem: The objective of this analysis was to esti-mate and compare the Cost Per Responder (CPR) based on the American College of Rheumatology outcomes (ACR 20/50/70) fol-lowing 48 weeks of treatment with secukinumab (SEC), the first and only fully human IL17-A antibody, relative to the anti-TNF ada-limumab (ADA), in Malaysia among biologic naive psoriatic arthritis (PsA) patients. Methodology & Theoretical Orientation: The CPR for each treatment was calculated by dividing the drug acquisition cost for the course of treatment with its response rate. Drug costs were based on IMS database for adalimumab and manu-facturers price for secukinumab in Malay-sia and the number of doses required for 48 weeks. The response rates originated from a recently published Matching-Adjusted Indirect Comparison (MAIC) based on the FUTURE 2 and ADEPT clin-ical trials of SEC and ADA, respectively. ACR 20 response rates were 80% vs. 74% vs. 56%, ACR 50 response rates were 57% vs. 61% vs. 44% and ACR 70 response rates were 32% vs. 43% vs. 30% in SEC 150mg, SEC 300mg and ADA, respective-ly. Findings: SEC shows consistently low-er CPR compared to ADA at 48 weeks. On average, the cost per ACR (20/50/70) responder on SEC 150mg was lower by 55% in comparison to ADA whereas the cost per ACR (20/50/70) responder on SEC 300mg was lower by 16% in comparison to ADA at week 48 (Figure 1). Conclusion & Significance: The CPR for the ACR 20, 50 and 70 outcomes at 48 weeks were consistently lower for SEC versus ADA. These findings indicate that PsA patients could be treated more efficiently with SEC over ADA in Malaysia.
Dr Fariz Yahya is a Rheumatologist and a Medical Lecturer. He qualified from Queens University of Belfast and obtained a Masters Degree in Internal Medicine from University of Malaya. He subsequently obtained his expert training in Rheumatology from the Royal National Hospital in Bath. Dr Fariz has been involved in numerous academic journals in studies of systemic lupus erythematous, systemic sclerosis, and ankylosing spondylitis. His latest academic journal includes “The Drug Survival of Anti-Tumour Necrosis Factor (TNF) Treatment in A UK Cohort of Axial Spondyloarthritis Patients” and “Drug survival for anti-TNF treatments in a UK cohort of axial spondyloarthritis patients”. Dr Fariz has been a member of the Malaysian Society of Rheumatology in 2013, and Persatuan SLE Malaysia in 2012. He is currently practicing in University Malaya Medical Center and teaching in Faculty of Medicine, University Malaya..